Corona Remedies Ltd

Corona Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Corona Remedies Ltd

₹ 1,589 -1.30%
12 Mar 4:01 p.m.
coronaremedies.com BSE: 544644 NSE: CORONA
About

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]

[ add key points ]
Website BSE NSE
  • Market Cap ₹ 9,716 Cr.
  • Current Price ₹ 1,589
  • High / Low ₹ 1,699 / 1,337
  • Stock P/E 60.9
  • Book Value ₹ 108
  • Dividend Yield 0.00 %
  • ROCE 31.5 %
  • ROE 27.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company has been maintaining a healthy dividend payout of 25.0%

Cons

  • Stock is trading at 14.8 times its book value
  • Promoter holding has decreased over last quarter: -3.50%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE IPO

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2024 Dec 2024 Jun 2025 Sep 2025 Dec 2025
314 298 347 361 342
247 228 277 283 259
Operating Profit 67 69 70 78 83
OPM % 21% 23% 20% 22% 24%
2 1 2 2 -17
Interest 3 2 2 2 2
Depreciation 9 10 9 9 9
Profit before tax 57 58 61 70 55
Tax % 25% 23% 24% 25% 25%
43 45 46 52 41
EPS in Rs 7.03 7.35 7.55 8.55 6.75
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
884 1,014 1,196
756 859 956
Operating Profit 128 156 241
OPM % 14% 15% 20%
7 5 6
Interest 4 14 11
Depreciation 20 28 37
Profit before tax 111 118 199
Tax % 23% 24% 25%
85 90 149
EPS in Rs 13.89 14.80 24.43
Dividend Payout % 20% 25% 30%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 18%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 64%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 23%
Last Year: 28%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 61 61 61 61
Reserves 347 419 545 598
28 159 86 63
159 191 237 254
Total Liabilities 595 831 930 977
185 384 370 394
CWIP 65 121 186 205
Investments 32 26 26 0
314 301 348 378
Total Assets 595 831 930 977

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
103 157 190
-50 -267 -84
-45 99 -107
Net Cash Flow 8 -11 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025
Debtor Days 36 36 36
Inventory Days 182 158 200
Days Payable 163 184 221
Cash Conversion Cycle 55 10 14
Working Capital Days 30 -2 9
ROCE % 25% 32%

Insights

In beta
Mar 2023Mar 2024Jun 2025
Actual Production - Total (Tablets/Capsules)
Million Units

Log in to view insights

Please log in to see hidden values.

Login
Capacity Utilization - Bhayla Tablets/Capsules
Percentage ・Standalone data
Chronic Segment Contribution to Revenue
Percentage
Installed Capacity - Tablets/Capsules (Total)
Million Units
IPM Market Rank
Rank
Market Share in Total IPM
Percentage
Number of Medical Representatives
Number
Number of Brands with Sales > INR 10 Crores
Number
Number of Distributors
Number

Shareholding Pattern

Numbers in percentages

6 Recently
Dec 2025
69.00%
1.84%
6.77%
22.41%
No. of Shareholders 31,035

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls